Aclaris Therapeutics Q3 net loss widens 27% to $18.51 million

Bitget2026/11/05 12:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aclaris Therapeutics’ third-quarter 2026 net loss widened 27% year over year to $18.51 million.
Revenue dropped 55% to $1.48 million, primarily due to a Sun Pharma licensing milestone achieved in the prior-year quarter.
October’s offering raised $50 million in gross proceeds; including net proceeds, cash runway is expected through the first half of 2029.
Bosakitug Phase 2 atopic dermatitis results and modzatinib Phase 2b lichen planus trial initiation are expected in fourth-quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050659PRIMZONEFULLFEED9870550) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aclaris Therapeutics Q3 net loss widens 27% to $18.51 million

You may also like

Crypto prices